1 ESGE recommends against diagnostic/therapeutic papillectomy when adenoma is not
proven. Strong recommendation, low quality evidence. 2 ESGE recommends endoscopic …

Background The effectiveness of prophylactic pancreatic duct stenting (PPDS) in preventing
post-ampullectomy pancreatitis (PAP) at the time of endoscopic ampullectomy (EA) has …

Upper gastrointestinal (GI) malignancy is a leading cause of cancer-related morbidity and
mortality. Upper endoscopy has an established role in diagnosing and staging upper GI …

Background: Endoscopic papillectomy is a minimally invasive treatment for benign tumors of
the ampulla of Vater or early ampullary carcinoma. However, reported recurrence rates are …

Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, the
intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct) …

Endoscopic resection techniques have evolved over time, allowing effective and safe
resection of the majority of pre-malignant and early cancerous lesions in the gastrointestinal …

Background Endoscopic papillectomy (EP) is an effective curative treatment in patients with
ampullary adenomas. However, EP is burdened by a not-negligible risk of bleeding. The aim …

Ampullary adenomatous lesions of the gastrointestinal tract are rare and can be
asymptomatic. Therefore, ampullary adenomas with malignant potential require prompt …

Background Ampullary adenomas are lesions at the duodenum's major papilla commonly
associated with familial adenomatous polyposis (FAP) but may also occur sporadically …

Ampullary neoplastic lesions (ANLs) represent a rare cancer, accounting for about 0.6–0.8%
of all gastrointestinal malignancies, and about 6–17% of periampullary tumors. They can be …